CH-0793076 TFA

Cat. No.: HY-107096B

CAS No.: 2740278-76-4

Molecular Formula: $C_{28}H_{27}F_3N_4O_6$

Molecular Weight: 572.53

Target: Topoisomerase

Pathway: Cell Cycle/DNA Damage

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 30 mg/mL (52.40 mM; Need ultrasonic)

Preparing Stock Solutions	Concentration / Solvent / Mass	1 mg	5 mg	10 mg
	1 mM	1.7466 mL	8.7332 mL	17.4663 mL
	5 mM	0.3493 mL	1.7466 mL	3.4933 mL
	10 mM	0.1747 mL	0.8733 mL	1.7466 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 3 mg/mL (5.24 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

CH-0793076 (TP3076) TFA, a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 TFA inhibits DNA topoisomerase I with an IC_{50} of 2.3 μM. CH-0793076 TFA is efficacious against cells expressing BCRP (breast cancer resistance protein)[1].

IC_{50} & Target

Topoisomerase I
2.3 μM (IC_{50})

In Vitro

CH0793076 (TP3076) TFA (6 days at 37°C) shows antiproliferative activity against PC-6/BCRP and PC-6/pRC cells, with IC_{50}s of 0.35 and 0.18 nM, respectively[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Endo M, et al. A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts. Cancer Chemother Pharmacol. 2010 Jan;65(2):363-71.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA